SCHEMBL25227852

SCHEMBL25227852

c1ccc(CCc2ccc3ncnc(N4CC5(CCNCC5)C4)c3c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.44
▸ CYP1A2 P05177 11/20 0.43
▸ CYP3A4 P08684 9/20 0.43
▸ HSD17B10 Q99714 7/20 0.43
▸ HPGD P15428 4/20 0.43
▸ LMNA P02545 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ TSHR P16473 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ ALDH1A1 P00352 7/20 0.43
▸ CLK4 Q9HAZ1 6/20 0.43
▸ CYP2C19 P33261 4/20 0.43
▸ IP6K1 Q92551 1/20 0.42
▸ IP6K3 Q96PC2 1/20 0.42
▸ IP6K2 Q9UHH9 1/20 0.42
▸ KIT P10721 2/20 0.41
▸ USP2 O75604 5/20 0.41
▸ AURKA O14965 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31501711 1.00 HTT (0.44) HTTCYP1A2CYP3A4HSD17B10HPGD
SCHEMBL31501707 0.90 CYP2D6 (0.46) HTTCYP1A2CYP3A4HSD17B10HPGD
SCHEMBL31501706 0.90 HTT (0.43) HTTCYP1A2CYP3A4HSD17B10HPGD
SCHEMBL25268625 0.90 CYP2D6 (0.46) HTTCYP1A2CYP3A4HSD17B10HPGD
SCHEMBL31501710 0.89 HTT (0.41) HTTCYP1A2CYP3A4HSD17B10HPGD
SCHEMBL25276551 0.89 CYP1A2 (0.51) HTTCYP1A2CYP3A4HSD17B10HPGD
SCHEMBL31501681 0.89 CYP1A2 (0.51) HTTCYP1A2CYP3A4HSD17B10HPGD
SCHEMBL31027439 0.89 CYP1A2 (0.51) HTTCYP1A2CYP3A4HSD17B10HPGD
SCHEMBL31501685 0.88 CYP1A2 (0.48) HTTCYP1A2CYP3A4HSD17B10HPGD
SCHEMBL31501696 0.87 CYP3A4 (0.48) HTTCYP1A2CYP3A4HSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163066-A1 PROTACs of MALT1 TEGID THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-20250163061-A1 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-20250066358-A1 Inhibitors of Menin-MLL Interaction BALA THERAPEUTICS, INC. 2025-02-27 — — US disclosed
EP-4482497-A2 PROTACS OF MALT1 Tegid Therapeutics, Inc. (US) 2025-01-01 — — EP disclosed
EP-4444313-A1 INHIBITORS OF MENIN-MLL INTERACTION Bala Therapeutics, Inc. (US) 2024-10-16 — — EP disclosed
EP-4444300-A2 INHIBITORS OF MENIN-MLL INTERACTION Bala Therapeutics, Inc. (US) 2024-10-16 — — EP disclosed
CN-118647378-A Inhibitors of Mei Nen protein interaction with MLL 巴拉疗法公司 2024-09-13 — — CN disclosed
WO-2023164175-A2 PROTACS OF MALT1 TEGID THERAPEUTICS, INC. (US) 2023-08-31 — — WO disclosed
WO-2023107687-A1 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. (US) 2023-06-15 — — WO disclosed
WO-2023107696-A2 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. (US) 2023-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163066-A1 PROTACs of MALT1 MALT1, BCL3, BCL9 HTT 819/4885CYP1A2 1635/4885CYP3A4 1574/4885
US-20250163061-A1 INHIBITORS OF MENIN-MLL INTERACTION MLLT1, MEN1, BMI1 HTT 3578/4885CYP1A2 3937/4885CYP3A4 4263/4885
US-20250066358-A1 Inhibitors of Menin-MLL Interaction MLLT1, MEN1, BMI1 HTT 3578/4885CYP1A2 3937/4885CYP3A4 4263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback